Department of Medicine, Columbia University, New York, NY 10032, USA.
Science. 2013 Jan 11;339(6116):166-72. doi: 10.1126/science.1230720.
A number of widespread and devastating chronic diseases, including atherosclerosis, type 2 diabetes, and Alzheimer's disease, have a pathophysiologically important inflammatory component. In these diseases, the precise identity of the inflammatory stimulus is often unknown and, if known, is difficult to remove. Thus, there is interest in therapeutically targeting the inflammatory response. Although there has been success with anti-inflammatory therapy in chronic diseases triggered by primary inflammation dysregulation or autoimmunity, there are considerable limitations. In particular, the inflammatory response is critical for survival. As a result, redundancy, compensatory pathways, and necessity narrow the risk:benefit ratio of anti-inflammatory drugs. However, new advances in understanding inflammatory signaling and its links to resolution pathways, together with new drug development, offer promise in this area of translational biomedical research.
许多广泛且具有破坏性的慢性疾病,包括动脉粥样硬化、2 型糖尿病和阿尔茨海默病,都具有病理生理学上重要的炎症成分。在这些疾病中,炎症刺激的确切性质通常是未知的,即使已知,也难以消除。因此,人们有兴趣通过治疗来靶向炎症反应。尽管在由原发性炎症失调或自身免疫引起的慢性疾病中,抗炎治疗已经取得了成功,但仍存在相当大的局限性。特别是,炎症反应对于生存至关重要。因此,冗余、补偿途径和必要性缩小了抗炎药物的风险收益比。然而,在炎症信号及其与解决途径的联系方面的新进展,以及新药的开发,为转化医学研究的这一领域带来了希望。